Compare Marriott International Inc (MAR) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marriott International Inc vs Recursion Pharmaceuticals Inc — how do they compare? Marriott International Inc trades at $368 (market cap $96.76B), while Recursion Pharmaceuticals Inc trades at $3.05 (market cap $1.53B). The key difference: Marriott International Inc is far larger — about 63.2× Recursion Pharmaceuticals Inc's market cap, and Marriott International Inc pays a 0.8% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| MAR | RXRX | |
|---|---|---|
Market Cap | $96.76B | $1.53B |
Sector | Consumer Cyclical | Health |
52-Week High | $402.54 | $6.79 |
52-Week Low | $255.35 | $2.84 |
Enterprise Value | $113.71B | $946.50M |
Dividend Yield | 0.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marriott International (MAR) trades at $366.83, up 0.16% on the day, with technical indicators showing a bearish trend near key support at $364. The company reported Q1 2026 EPS of $2.72, beating expectations, and maintains a net income margin of 9.72% amid steady revenue growth. Recent developments include a strategic partnership with Coca-Cola and the launch of an AI-powered travel search tool, Ask Bonvoy, enhancing its digital offerings.
The outlook is mixed: analyst consensus targets $387.92 with 44% buy ratings, but rising debt-to-asset ratios and hotel owner disputes over the Bonvoy program pose risks. Earnings on August 3, 2026, will be critical for confirming growth trajectory amid competitive travel sector pressures.
RXRX trades at $2.89, down 1.87% on the day, reflecting a challenging fundamental backdrop with a net income margin of -851.51% and negative cash flow from operations. The technical picture is bearish, though the stock has beaten earnings estimates for the last three quarters. Recent news highlights its AI-driven drug discovery platform and significant institutional interest, including purchases by Cathie Wood's Ark Invest.
The outlook remains speculative; the high analyst price target of $7.83 suggests significant upside potential, but this is contingent on the company successfully commercializing its pipeline. Key risks include persistent cash burn, intense competition, and the inherent uncertainty of clinical-stage biotech development.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
